hsa-miR-328

ncRNA information

ncRNA name

hsa-miR-328

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Prognosis/Treatment

Upstream regulatory factors

Not available

Downstream target

PTEN

Cancer information

Cancer name

Non-Small Cell Lung Cancer

Cancer site

Lung

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Up

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Abnormal expression of miR-328 may contribute to cisplatin resistance in NSCLC, and may be considered to be a novel therapeutic target and indicator for the treatment and prognosis of patients with NSCLC treated with cisplatin-based chemotherapy.

Tissue resource

non-small cell lung cancer tissue samples

human non-small cell lung cancer cell lines A549

cisplatin-resistant A549 sublines A549rCDDP

Experiment

qRT-PCR,Western blot,Dual-luciferase reporter assay


Institute

Dezhou People's Hospital

the Cancer Hospital of Peking Union Medical College, Chinese Academy of Medical Sciences

Country

China

Continent

Asia